These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17766736)

  • 21. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
    de Boer HD; van Esmond J; Booij LH; Driessen JJ
    Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correspondence Letter to the Editor regarding 'The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex' by Langley, McFadzean & McCormack.
    Ekeoduru R; Lin M; Matuszczak M
    Paediatr Anaesth; 2016 Jul; 26(7):773-4. PubMed ID: 27277656
    [No Abstract]   [Full Text] [Related]  

  • 23. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G; Pompei L
    Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of sugammadex in a patient with myasthenia gravis.
    Unterbuchner C; Fink H; Blobner M
    Anaesthesia; 2010 Mar; 65(3):302-5. PubMed ID: 20105151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drug sugammadex: a selective relaxant binding agent.
    Welliver M
    AANA J; 2006 Oct; 74(5):357-63. PubMed ID: 17048555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A reply.
    Tomak Y; Erdivanli B; Kalkan Y; Tumkaya L
    Anaesthesia; 2013 Feb; 68(2):209. PubMed ID: 23298350
    [No Abstract]   [Full Text] [Related]  

  • 28. Allergy to low dose sugammadex.
    Menéndez-Ozcoidi L; Ortiz-Gómez JR; Olaguibel-Ribero JM; Salvador-Bravo MJ
    Anaesthesia; 2011 Mar; 66(3):217-9. PubMed ID: 21320089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions.
    Akha AS; Rosa J; Jahr JS; Li A; Kiai K
    Anesthesiol Clin; 2010 Dec; 28(4):691-708. PubMed ID: 21074746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo animal studies with sugammadex.
    Booij LH; van Egmond J; Driessen JJ; de Boer HD
    Anaesthesia; 2009 Mar; 64 Suppl 1():38-44. PubMed ID: 19222430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical implications of sugammadex.
    Caldwell JE; Miller RD
    Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sugammadex: a novel neuromuscular blocker binding agent.
    Fields AM; Vadivelu N
    Curr Opin Anaesthesiol; 2007 Aug; 20(4):307-10. PubMed ID: 17620836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecule of the month. Sugammadex sodium.
    Drug News Perspect; 2007 Nov; 20(9):591-2. PubMed ID: 18176664
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
    White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
    Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An update on sugammadex sodium.
    Welliver M; Cheek D
    AANA J; 2009 Jun; 77(3):219-28. PubMed ID: 19645172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O; White PF; Tufanogullari B; Klein K
    Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New neuromuscular blockers: mivacurium and rocuronium].
    González-Miranda F; Solera J
    Rev Esp Anestesiol Reanim; 1997 Oct; 44(8):297-8. PubMed ID: 9424680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.